...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
【24h】

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

机译：2007年至2010年，在八个非洲国家开展了预防黄热病疫苗接种运动后的不良事件。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Serious, but rare adverse events following immunization (AEFI) have been reported with yellow fever (YF) 17D vaccine, including severe allergic reactions, YF vaccine-associated neurologic disease (YEL-AND) and YF vaccine-associated viscerotropic disease (YEL-AVD). The frequency with which YEL-AND and YEL-AVD occur in YF endemic countries is mostly unknown. Methods: From 2007 to 2010, eight African countries - Benin, Cameroon, Guinea, Liberia, Mali, Senegal, Sierra Leone, and Togo-implemented large-scale YF preventive vaccination campaigns. Each country established vaccine pharmacovigilance systems that included standard case definitions, procedures to collect and transport biological specimens, and National Expert Committees to review data and classify cases. Staff in all countries received training and laboratory capacity expanded. Results: In total, just over 38 million people were vaccinated against YF and 3116 AEFIs were reported of which 164 (5%) were classified as serious. Of these, 22 (13%) were classified as YF vaccine reactions, including 11 (50%) hypersensitivity reactions, six (27%) suspected YEL-AND, and five (23%) suspected YEL-AVD. The incidence per 100,000 vaccine doses administered was 8.2 for all reported AEFIs, 0.43 for any serious AEFI, 0.058 for YF vaccine related AEFIs, 0.029 for hypersensitivity reactions, 0.016 for YEL-AND, and 0.013 for YEL-AVD. Our findings were limited by operational challenges, including difficulties in obtaining recommended biological specimens leading to incomplete laboratory evaluation, unknown case ascertainment, and variable levels of staff training and experience. Conclusions: Despite limitations, active case-finding in the eight different countries did not find an incidence of YF vaccine associated AEFIs that was higher than previous reports. These data reinforce the safety profile of YF vaccine and support the continued use of attenuated YF vaccine during preventive mass vaccination campaigns in YF endemic areas.Digital Object Identifier http://dx.doi.org/10.1016/j.vaccine.2013.01.054
机译：背景：黄热病（YF）17D疫苗曾发生严重但罕见的免疫不良反应（AEFI），包括严重的过敏反应，YF疫苗相关的神经系统疾病（YEL-AND）和YF疫苗相关的内脏疾病（YEL） -AVD）。在YF流行国家中，YEL-AND和YEL-AVD发生的频率几乎是未知的。方法：从2007年到2010年，八个非洲国家-贝宁，喀麦隆，几内亚，利比里亚，马里，塞内加尔，塞拉利昂和多哥实施了大规模的YF预防接种运动。每个国家都建立了疫苗药物警戒系统，其中包括标准病例定义，收集和运输生物标本的程序以及国家专家委员会，以审查数据和对病例进行分类。所有国家的工作人员都接受了培训，实验室的能力得到了扩大。结果：总共有超过3,800万人接种了YF疫苗，并报告了3116枚AEFI，其中164例（5％）被归为严重。其中22种（13％）被归类为YF疫苗反应，包括11种（50％）超敏反应，6种（27％）可疑YEL-AND和5种（23％）可疑YEL-AVD。对于所有报告的AEFI，每100,000剂疫苗接种的发生率分别为8.2，任何严重AEFI为0.43，与YF疫苗相关的AEFI为0.058，超敏反应为0.029，YEL-AND为0.016和YEL-AVD为0.013。我们的发现受到操作挑战的限制，包括难以获得推荐的生物学标本，导致实验室评估不完整，病例查明不明以及人员培训和经验水平不一。结论：尽管存在局限性，但在八个不同国家中进行积极的病例调查并未发现YF疫苗相关AEFI的发生率高于先前的报告。这些数据加强了YF疫苗的安全性，并支持在YF流行地区进行预防性大规模疫苗接种运动期间继续使用减毒YF疫苗。数字对象标识符http://dx.doi.org/10.1016/j.vaccine.2013.01.054

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号